Many of today’s top organizations, businesses, or companies all have one thing in common. These successful institutions are profit driven while providing valuable services/products to the general public and Biotech giant Seattle Genetics is no exception. Seattle Genetics is a company that specializes in the development and commercialization of Antibody Based Therapies. These advanced breakthrough therapies are some of the most commonly used medications in the world and does a great job at fighting cancer. The antibody drug conjugates attack dangerous cancer cells in the body and delivers cell killing agents directly into the cells in question.
Seattle Genetics is at the apex of the field, but who is actually steering the ship? Have you ever heard of Clay Siegall? Did you know that he is one of the most prominent figures in cancer research? That’s right! Dr. Clay Siegall embodies the company’s work through his use of advanced technology, extensive research capabilities, and drug development practices. Dr. Siegall has been in the game for many years and has worked with many of the top medical institutions such as:
The National Institute of Health
Bristol Myers Squibb
The National Cancer Institute
The good doctor has a (BS) in Zoology from the University of Maryland and a Ph.D in Genetics from George Washington University. Siegall might just be overqualified for the role thanks to his brilliant mind and strong commitment to help others. Early in 2016, this Bothell, Washington company was visited by Vice President Joe Biden in the wake of it’s current growth explosion and (Forbes Magazine) listed Seattle Genetics as one of the fastest growing companies of 2016. Dr. Clay Siegall’s influence shines through from the advanced technology, all the way to the actual patients themselves.
Currently the company has 12 drugs in the development stages and the drugs listed aren’t the company’s most successful drug (ADCETRIS). The future is looking brighter for cancer patients and combine that with the experience of Dr. Clay Siegall, “the sky is the limit or should I say, the limit is the sky.”
Cancer has been a threatening chronic illness in the world. Scientist has been carrying out numerous studies to come up with a solution to the treatment of the disease. One of the company includes Seattle Genetics. Seattle Genetics and Clay Siegall have been involved in the development of cancer treatment since it was established.
Seattle Genetics is a pharmaceutical firm which has a primary mandate of developing as well as researching on cancer treatment drugs. Seattle focuses on innovating new monoclonal antibodies options for genetics. The company can be described as one of the leaders in the creation and the commercialization of antibodies drugs for cancer treatment. Seattle Genetics develop Antibody-drug Conjugates (ADCs). The technology is well designed to connect the ability of monoclonal antibodies to distribute cell-killing agents directly to the cancer cells. The drugs are intended to spare the harmless cells in the body and according to the studies it helps in the reduction of toxic effects of the tradition cancer treatment chemotherapy at the same time assisting in the enhancement of antitumor activities in the body.
Seattle Genetics have collaborated with other companies including Takeda Pharmaceutical Company to develop the drugs such as Adcetris. The drug helps in the treatment of cancer types including Lymphoma, mature T-cells lymphoma, B-cells lymphoma, cutaneous T-cells lymphoma, as well as Hodgins lymphoma. Seattle has taken the full right of commercializing the drug in the United States and Canada while Takeda has the exclusive rights to sell the drug in other countries.
Seattle Genetics was founded in 1998 by Clay Siegall and has its Headquarters in Bothell Washington. Their employees are well trained and have a passion for helping the cancer patients.
Clay Siegall is the co- founder the Chief Executive Officer, the President and the Chairman of the Board of Seattle Genetics. Clay is a scientist by professional, and he is dedicated and very passionate about helping the cancer patients in the world. The company Seattle Genetics is built under scientific modernizations, demanding research as well as the development of cancer treatment drugs. Before he co-founded Seattle Genetics, Clay served in several others leading medical institutions including Bristol-Myers Squibb Pharmaceuticals Research Institute, National Cancer Institute, and the National Institute of Health.
Clay Siegall has a vast experience in the medical sector and is very passionate about cancer treatment, and he has served on the board of director in Ultragenyx Pharmaceuticals and Alder BioPharmaceuticals among others. Recently Siegall mentioned that the company is out to develop more drugs to assist the cancer patients and fulfill the unmet medical needs.
Seattle Genetics is in the news again thanks to it’s brilliance in the fight against cancer. The company is experiencing dramatic growth from it’s enlarging pipeline of pharmaceutical drugs, resulting in another hiring spree which will bring the total number of employees to approximately 800 people. This premier cancer research center’s most commercialized drug is currently being tested in more than 70 trials. Lymphomas are largely treated withAdcetrisand the drug racked up $226 Million in sales for 2015 in Canada and the U.S. The expected progression for 2016 in the two countries is looking at the range of up to $275 Million. In light of the news, Vice President Joe Biden visited Puget Sound’s famous research center and it seems the media is having a field day on covering the interaction between the two. Adcetris is currently in Phase-3 Clinical Trial for newly or untreated Hodgkin Lymphoma. The results of these Trials are expected to have the largest impact of Seattle Genetics this year. Adcetris might be the face of the company, but there are 12 other drugs in development at present time. Seattle Genetics is definitely looking toward the future and company president Clay Siegall is leading the charge.
Dr. Clay Siegall is a George Washington University Graduate with a Ph.D in Genetics. The good doctor also has a (B.S.) in Zoology from the University of Maryland and currently holds 15 patents to date. Before the genesis of Seattle Genetics, Dr. Siegall has worked with the finest in this industry.GlaxoSmithKlein, Bristol-MyersSquibb, National Institute of Health, and National Cancer Instituteto name a few. Dr. Sigall embodies the words philanthropist and revolutionary for his valiant efforts in the fight against cancer.
Clay Siegall is also a scientist by training, a pioneer in the development of (ADC’s) Anti-body Drug Conjugates, author of up to 70 publications, and has led the company in capital-raising activities. Seattle Genetics has a bright future as well as the patients who benefit from these advanced innovations.
The biotech firm Seattle Genetics recently expanded its public stock offerings during its most recent funding efforts. Initially the firm had placed its public stock offerings at $480 Million, but due to the roaring success Seattle Genetics expanded its public stock offerings to $552 million. Currently known for its innovation and breakthroughs, the firm has signed agreements with giants like Pfizer to advance cancer therapy. The revenue Seattle Genetics gained will help the biotech firm advance its research into better ways to fight cancer.
The success of its antibody drug conjugates has reduced many of the undesirable side effects of cancer treatment without reducing the quality of treatment. ADCs target malignant cells but leave healthy cells intact. Many of the problems cancer patients face during their ordeals comes from the damage done to healthier parts of the body by the therapy they are undergoing. Without that cellular damage patients stand a much better chance of beating the disease.
The CEO of Seattle Genetics, Clay Siegall, has spent nearly 30 years researching cancer and developing solutions to the issue of cancer. In the 1988 he first entered the world of cancer research through his work at the National Cancer Institute. After working there for 3 years he worked for the Bristol-Myers Squibb Pharmaceutical Research Institute between the years 1991 and 1997. When Clay Siegall left Bristol-Myers he founded Seattle Genetics one year later. Using his experience in cancer research he and his team at Seattle Genetics went to work on ways to make the experience and outcome of cancer patients better. Clay Siegall’s success has led to other biotech firms giving him a position on their boards for directors such as Mirna Therapeutics. The results of their efforts produced the antibody drug conjugate. This innovation has become so important that Seattle Genetics is able to generate hundreds of millions of dollars in funding to continue to advance its projects.
Mirna Therapeutics, Inc. is a leading Biotechnology Corporation, founded in Austin, Texas, has appointed Dr. Clay Siegall, Ph.D., as of 2013, as a Board of Directors outside member, which is a member of a company’s board of directors, not employed by said company and is not salaried. There is a yearly retainer given, either as cash, or benefits agreed upon.
Public companies are required to maintain a said amount of these outside directors on their board because it is thought that they will have no conflict of interest and will give unbiased opinions.
Mirna Therapeutics is centered on MicroRNA therapeutics and cancer research, which Clay B. Siegall has broad experience in, and they are sure Dr. Siegall will be an excellent guide in their goal to advance MicroRNA therapeutics’ development of programs to benefit patients who need help asap.
Dr. Clay Siegall earned his Bachelor of Science in Zoology at the University of Maryland and earned his Ph.D. in Genetics at the George Washington University.
Dr. Clay Siegall is the 1998 Co-Founder of Seattle Genetics and Biotechnology. He is also their President, CEO, and Chairman of The Board. Dr. Siegall has a Ph.D. And is a scientist with a drive to find cancer therapies that will aid patients quickly in their battle with cancer.
He and Seattle Genetics have made great progress in this area. Seattle Genetics is a leader in the field of development of antibody-drug conjugates (ADCs) for cancer treatments. Seattle Genetics, under Dr. Seagall’s leadership, has moved into various strategic licenses for these
Dr. Clay Siegall, Ph.D., is on Ultragenyx Pharmaceutical’s Board of directors since 2014, and is a board member of Alder Biopharmaceuticals, Inc., since 2006. Dr. Siegall is also an Author, with entries into over 70 publications, and holds 15 patents, currently. Clay Siegall was named Alumnus of The Year for Computer, Math, and Natural Sciences in 2013, from the University of Maryland and he won Entrepreneur of the year at Pacific Northwest Ernst & Young in 2012.